{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mogamulizumab-Kpkc",
    "query": {
      "intervention": "Mogamulizumab-Kpkc"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mogamulizumab-Kpkc&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T03:23:33.541Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02301130",
      "title": "Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "mogamulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4736 (Durvalumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2014-11-26",
      "completion_date": "2018-03-05",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02301130"
    },
    {
      "nct_id": "NCT03309878",
      "title": "Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma",
        "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory Transformed B-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Mogamulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-10-24",
      "completion_date": "2023-04-11",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 8,
      "location_summary": "Sacramento, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03309878"
    },
    {
      "nct_id": "NCT04541017",
      "title": "Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mycosis Fungoides",
        "Recurrent Mycosis Fungoides",
        "Recurrent Mycosis Fungoides and Sezary Syndrome",
        "Recurrent Sezary Syndrome",
        "Refractory Mycosis Fungoides",
        "Refractory Mycosis Fungoides and Sezary Syndrome",
        "Refractory Sezary Syndrome",
        "Sezary Syndrome",
        "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magrolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mogamulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Punch Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2021-04-06",
      "completion_date": "2024-10-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 18,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541017"
    },
    {
      "nct_id": "NCT04745234",
      "title": "Mogamulizumab Q4week Dosing in Participants With R/R CTCL",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous T-Cell Lymphoma, Relapsed",
        "Cutaneous T-Cell Lymphoma Refractory"
      ],
      "interventions": [
        {
          "name": "Mogamulizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2021-08-16",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Irvine, California • Stanford, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04745234"
    },
    {
      "nct_id": "NCT04185220",
      "title": "Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult T-Cell Lymphoma/Leukemia",
        "Sezary Syndrome",
        "Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Recombinant human Interleukin-15 (rhIL-15)",
          "type": "DRUG"
        },
        {
          "name": "Mogamulizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-02-26",
      "completion_date": "2022-05-18",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04185220"
    },
    {
      "nct_id": "NCT01626664",
      "title": "KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult T-cell Leukemia-Lymphoma"
      ],
      "interventions": [
        {
          "name": "KW-0761",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pralatrexate",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine plus oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "DHAP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2012-06",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01626664"
    },
    {
      "nct_id": "NCT05996185",
      "title": "Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T Cell Lymphoma",
        "T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Mogamulizumab",
          "type": "DRUG"
        },
        {
          "name": "DA-EPOCH Protocol",
          "type": "DRUG"
        },
        {
          "name": "CHOEP protocol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2024-10-09",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • New York, New York",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05996185"
    },
    {
      "nct_id": "NCT06235281",
      "title": "Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Mogamulizumab-Kpkc",
          "type": "DRUG"
        },
        {
          "name": "Phototherapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-01-18",
      "completion_date": "2029-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06235281"
    },
    {
      "nct_id": "NCT04676087",
      "title": "Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mycosis Fungoides",
        "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Sezary Syndrome"
      ],
      "interventions": [
        {
          "name": "Extracorporeal Photopheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Mogamulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-04-21",
      "completion_date": "2023-10-11",
      "has_results": false,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676087"
    },
    {
      "nct_id": "NCT04930653",
      "title": "Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Folliculotropic Mycosis Fungoides",
        "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Sezary Syndrome",
        "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Transformed Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Extracorporeal Photopheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Mogamulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2022-10-19",
      "completion_date": "2028-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-27T03:23:33.541Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Atlanta, Georgia",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04930653"
    }
  ]
}